Drug Trial Radar · NCT02859948
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
May 2016
Primary completion
Dec 2017
Study completion Jan 2018
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.
Conditions
- Acute Myeloid Leukemia
Interventions
SKLB1028Drug
SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Incidence of dose limiting toxicity (DLT)and Adverse Event (AE)Time frame: 28 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital,Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.